Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis.

Simon KC, O'Reilly EJ, Munger KL, Finerty S, Morgan AJ, Ascherio A.

Mult Scler. 2012 Aug;18(8):1185-7. doi: 10.1177/1352458511433920. Epub 2012 Jan 30.

2.

Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis.

De Jager PL, Simon KC, Munger KL, Rioux JD, Hafler DA, Ascherio A.

Neurology. 2008 Mar 25;70(13 Pt 2):1113-8. doi: 10.1212/01.wnl.0000294325.63006.f8. Epub 2008 Feb 13.

PMID:
18272866
3.

Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.

Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A.

JAMA. 2005 May 25;293(20):2496-500.

PMID:
15914750
4.

Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.

Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, Olek MJ, Hankinson SE, Hunter DJ.

JAMA. 2001 Dec 26;286(24):3083-8.

PMID:
11754673
5.

Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.

Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, Khaleeli Z, Schmierer K, Miller DH, Giovannoni G.

Neurology. 2009 Jul 7;73(1):32-8. doi: 10.1212/WNL.0b013e3181aa29fe. Epub 2009 May 20.

6.

Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples.

Salzer J, Nyström M, Hallmans G, Stenlund H, Wadell G, Sundström P.

Mult Scler. 2013 Oct;19(12):1587-91. doi: 10.1177/1352458513483888. Epub 2013 Apr 2.

PMID:
23549431
7.

Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.

Munger KL, Levin LI, O'Reilly EJ, Falk KI, Ascherio A.

Mult Scler. 2011 Oct;17(10):1185-93. doi: 10.1177/1352458511408991. Epub 2011 Jun 17.

8.

Multiple sclerosis and Epstein-Barr virus.

Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A.

JAMA. 2003 Mar 26;289(12):1533-6. Retraction in: Ascherio A, Rubertone M, Spiegelman D, Levin L, Munger K, Peck C, Lennette E. JAMA. 2005 May 25;293(20):2466.

PMID:
12672770
9.

Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up.

DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A.

Arch Neurol. 2006 Jun;63(6):839-44. Epub 2006 Apr 10.

PMID:
16606758
10.

High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.

Coghill AE, Bu W, Nguyen H, Hsu WL, Yu KJ, Lou PJ, Wang CP, Chen CJ, Hildesheim A, Cohen JI.

Clin Cancer Res. 2016 Jul 15;22(14):3451-7. doi: 10.1158/1078-0432.CCR-15-2299. Epub 2016 Feb 26.

11.

Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis.

Lindsey JW, Hatfield LM, Vu T.

Eur J Neurol. 2010 Oct;17(10):1263-9. doi: 10.1111/j.1468-1331.2010.03005.x.

12.

Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.

Perez EM, Foley J, Tison T, Silva R, Ogembo JG.

Oncotarget. 2017 Mar 21;8(12):19255-19273. doi: 10.18632/oncotarget.13770.

13.

Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.

Ruprecht K, Wunderlich B, Gieß R, Meyer P, Loebel M, Lenz K, Hofmann J, Rosche B, Wengert O, Paul F, Reimer U, Scheibenbogen C.

J Neuroimmunol. 2014 Jul 15;272(1-2):56-61. doi: 10.1016/j.jneuroim.2014.04.005. Epub 2014 Apr 16.

PMID:
24798244
14.

Association of Epstein-Barr virus infection with multiple sclerosis in India.

Pandit L, Malli C, D'Cunha A, Shetty R, Singhal B.

J Neurol Sci. 2013 Feb 15;325(1-2):86-9. doi: 10.1016/j.jns.2012.12.004. Epub 2013 Jan 9.

PMID:
23312038
15.

The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.

Najafipoor A, Roghanian R, Zarkesh-Esfahani SH, Bouzari M, Etemadifar M.

Cell Immunol. 2015 Mar;294(1):9-12. doi: 10.1016/j.cellimm.2015.01.009. Epub 2015 Jan 28.

PMID:
25666504
16.

A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma.

Bertrand KA, Birmann BM, Chang ET, Spiegelman D, Aster JC, Zhang SM, Laden F.

Blood. 2010 Nov 4;116(18):3547-53. doi: 10.1182/blood-2010-05-282715. Epub 2010 Jul 20.

17.

Plasma viral load of Epstein-Barr virus and risk of multiple sclerosis.

Wagner HJ, Munger KL, Ascherio A.

Eur J Neurol. 2004 Dec;11(12):833-4.

PMID:
15667414
18.

Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis.

Almohmeed YH, Avenell A, Aucott L, Vickers MA.

PLoS One. 2013 Apr 9;8(4):e61110. doi: 10.1371/journal.pone.0061110. Print 2013. Review.

19.

Altered prevalence and reactivity of anti-Epstein-Barr virus antibodies in patients with multiple sclerosis.

Wagner HJ, Hennig H, Jabs WJ, Siekhaus A, Wessel K, Wandinger KP.

Viral Immunol. 2000;13(4):497-502.

PMID:
11192296
20.

Antibody titers against EBNA1 and EBNA2 in relation to Hodgkin lymphoma and history of infectious mononucleosis.

Mueller NE, Lennette ET, Dupnik K, Birmann BM.

Int J Cancer. 2012 Jun 15;130(12):2886-91. doi: 10.1002/ijc.26334. Epub 2011 Aug 30.

Supplemental Content

Support Center